- Home
- Equipment
- canada quebec
- clinical proof
Clinical Proof Equipment & Supplies In Quebec
21 equipment items found
Manufactured by:Pain Care Labs based inAtlanta, GEORGIA (US) (USA)
Buzzy Mini Healthcare features a contoured and compact design that tucks under a standard tourniquet or fits easily in the hand to deliver powerful pain blocking right where you need it. Patented M-Stim™ mechanical stimulation and ice technology blocks pain on contact. Intended for healthcare and multi-patient use, or those that desire a healthcare grade unit. Features 3 minute auto-shutoff ...
Manufactured by:BridgeBio Pharma, Inc. based inPalo Alto, CALIFORNIA (USA)
BridgeBio is working to create a potential first-ever systemic treatment for dystrophic epidermolysis bullosa (DEB), a disease caused by loss of function of Collagen 7 (C7) protein. PTR-01 is a C7 protein replacement therapy designed to restore the missing collagen protein (C7) at the root of the disease. Mutations in the gene that encodes C7 enable the epidermis to separate from the dermis. Even ...
Manufactured by:Caelus Health based inAmsterdam, NETHERLANDS
Intestinimonas: as basis of a drug to treat Type 2 Diabetes has been tested in animal trials; a first clinical Proof of Concept study will start in ...
Manufactured by:BridgeBio Pharma, Inc. based inPalo Alto, CALIFORNIA (USA)
Infigratinib (BGJ398), is an orally administered, ATP-competitive, FGFR1-3 tyrosine kinase inhibitor in development for the treatment of FGFR-driven conditions, including achondroplasia, a bone growth disorder in children. Overactivating FGFR3 mutations drive downstream MAPK and STAT1 signaling that aberrates growth plate development, thereby causing disproportionate short stature and serious ...
Manufactured by:Futura Medical based inGuildford, UNITED KINGDOM
Scientific advisory meeting held with MHRA confirming the need of a Phase 3 study to support the improved skin permeation including potential superior efficacy claims. Exploring the feasibility of a clinical study to satisfy the Phase 3 requirements for both UK and US approval. Development currently on ...
Manufactured by:Vivesto AB based inSolna, SWEDEN
Cantrixil is a product candidate in clinical stage being developed for the treatment of ovarian cancer. Cantrixil consists of the active molecule, a potent and selective third generation benzopyran SMETI inhibitor named TRXE-002-01, encapsulated in a cyclodextrin. It is believed to target a wide spectrum of cancer cells, including chemotherapy-resistant tumor-initiating cells that are thought to ...
Manufactured by:Kiadis Pharma NV based inAmsterdam, NETHERLANDS
K-NK003: A phase 1 study evaluating NK cells as a treatment for patients with relapse and refractory acute myeloid leukemia (AML). This study was designed based on promising clinical proof-of-concept data from two studies, one at MD Anderson Cancer Center and one at HCPA in ...
Manufactured by:BiomX based inNess Ziona, ISRAEL
BiomX develops phage cocktails (or combinations) that target and kill specific pathogenic bacteria. Our phage cocktails, which are optimized through algorithms and experimental validation (in-vitro and in-vivo), contain multiple natural and/or engineered phage. The phage are selected to have complementary functions such as wide target bacterial host range and the ability to avoid the development ...
by:STALICLA based inGeneve, SWITZERLAND
STALICLA’s precision medicine approach begins with ‘endophenotyping’-identifying the nonbehavioral physical and molecular presentations of NDDs and characterizing subgroups of patients with similar disease signatures. DEPI matches these patient subgroups with an NDD-targeted drug (or drug combination) by integrating and analyzing large omics data sets, including genomics, ...
by:Blueback Physio based inPacé, FRANCE
As often in entrepreneurship, the idea of BlueBack was born from a personal story. The story of a young woman who at the age of twenty, was forbidden to practice sports because of back pain. After a long medical journey (specialized doctor, specialized rehabilitation center...), the real cause of the pathology is not treatable unless the resumption of a regular physical activity with as a ...
by:AdAlta Limited based inBundoora, AUSTRALIA
AdAlta and Carina Biotech to develop next-generation i-body enabled CAR-T cancer therapeutics. AdAlta has entered a collaboration agreement with Carina Biotech to develop next-generation i-body enabled CAR-T cells, with the potential to bring CAR-T cell therapy to treat a far greater range of cancers than the small number of blood cancers that has been achieved today. Under the Collaboration ...
Manufactured by:Kiadis Pharma NV based inAmsterdam, NETHERLANDS
K-NK002: A phase 2 clinical study evaluating haplo-identical NK cells to prevent post-transplant relapse in patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). This study was designed based on promising clinical proof-of-concept data from MD Anderson Cancer Center. The phase 2 trial for K-NK002 will be conducted in collaboration with the Bone Marrow Transplant Clinical ...
Manufactured by:Cellanyx, LLC based inBeverly, MASSACHUSETTS (USA)
Risk stratification of early-stage breast cancer is an active area of research and several commercially available products that are based on genotypic classification. A vexing issue in breast cancer is carcinoma in situ – which has no metastatic potential. There are two sub types – Ductal Carcinoma in Situ (DCIS) and Lobular Carcinoma in Situ (LCIS). The incidence of these entities is ...
by:Sorrento Therapeutics, Inc. based inSan Diego, CALIFORNIA (USA)
RTX (resiniferatoxin) is a unique neural intervention molecule that is highly selective and may be applied peripherally (e.g., nerve block, intra-articular) or centrally (e.g., epidural), to control chronic pain across multiple conditions including arthritis and cancer. RTX has the potential to be a first-in-class drug addressing currently intractable pain in a novel and unique way, by targeting ...
Manufactured by:Vaxcyte, Inc. based inSan Carlos, CALIFORNIA (USA)
We believe our clinical-stage company is uniquely positioned to create vaccines that can overcome bacteria’s formidable defense mechanisms and be produced on a significant scale. We are leveraging our XpressCF™ cell-free protein synthesis platform to create high-fidelity vaccines featuring distinct protein carriers and antigens – the critical building blocks of vaccines ...
Manufactured by:AC BioScience SA based inEpalinges, SWITZERLAND
Our medical objective is to validate and bring to clinical use, a novel approach to improve the treatment of metastatic pancreatic adenocarcinoma using a proangiogenic molecule S1P lyase inhibitor acting as a tumor vascular ...
Manufactured by:EsoCap AG based inBasel, SWITZERLAND
EsoCap owns a unique drug delivery platform allowing the topical application of drug substances for targeted and long-lasting treatment of diseases of the upper gastrointestinal tract for the first ...
Manufactured by:CyberKnife, by Accuray Incorporated based inMadison, WISCONSIN (USA)
The CyberKnife System is a non-invasive treatment for cancerous and non-cancerous tumors and other conditions where radiation therapy is indicated. It is used to treat conditions throughout the body, including the prostate, lung, brain, spine, head and neck, liver, pancreas and kidney, and can be an alternative to surgery or for patients who have inoperable or surgically complex tumors. ...
by:CuraVac Europe S.A. based inRixensart, BELGIUM
The MYASTERIX project (2013 – 2018) advanced a Therapeutic Vaccine candidate (designated orphan drug) indicated for myasthenia gravis (MG) to clinical proof of concept ...
Manufactured by:Lattice Medical based inLoos, FRANCE
Lattice Medical is a biomedical start-up that was launched in October 2017; Patented 3D technology developed with CHU Lille-France that allows adipose tissue to naturally ...